Jump to content

Vaginal / Sexual and HRT Risks in Menopause/Data

From RiskiPedia
Vaginal / Sexual and HRT Risks in Menopause/Data:SymptomSeverity Mitigation
MitigationStrategy Symptom_Improvement_Percent Associated_Risks_Text

No Treatment

0

No associated risks.

Local HRT

80

Local HRT has a very low risk profile with minimal systemic absorption.

Systemic HRT

90

For every 1,000 women who use systemic HRT for 5 years, there are approximately 4 additional cases of breast cancer. The risk of a blood clot is about 8 additional cases per 10,000 women per year with oral HRT.

Non-Hormonal Lubricants/Moisturizers

50

Non-hormonal treatments have a very low risk profile.

The table above shows the approximate percentage of women who report significant improvement in genitourinary symptoms of menopause (GSM) based on different mitigation strategies. The associated risks for systemic HRT are based on a 5-year period.

  RiskModel: Vaginal / Sexual and HRT Risks in Menopause/Data:GSM_Risk_Model
    Content: 
'''Selected Mitigation Strategy:''' {MitigationStrategy}
<br>
The likelihood of significant symptom improvement has a {Symptom_Improvement_Percent}% chance of success.
<br><br>
'''Associated Risks:'''
<br>
{Associated_Risks_Text}

The baseline risk of developing symptoms is between 40% and 84%.

Data and risk models are used on the main page.

Is there a significant difference in treatment results based on the stage of menopause?

Based on a review of medical and scientific literature, the most significant factor in the effectiveness of Hormone Replacement Therapy (HRT) for vaginal and sexual symptoms is the type of HRT (local vs. systemic), not necessarily the stage of menopause when it's initiated. However, the timing of initiation does play a role in the overall risk profile of systemic HRT.

Here is a summary of the data regarding the timing of HRT initiation for vaginal and sexual symptoms:

  • Symptoms are Progressive: Genitourinary Syndrome of Menopause (GSM), which includes vaginal dryness, pain, and other symptoms, is a chronic and progressive condition caused by a lack of estrogen. These symptoms do not improve with time and can worsen if left untreated.
  • Local vs. Systemic HRT:
    • Local HRT (creams, rings, or tablets inserted vaginally) is considered the gold standard for treating GSM symptoms when they are the primary concern. It has a very low risk profile because it delivers estrogen directly to the vaginal tissues with minimal systemic absorption. It is effective regardless of how long a woman has been in menopause.
    • Systemic HRT (pills, patches, gels) is typically used for women who have other significant menopausal symptoms, such as hot flashes. While also effective for GSM, a key consideration for its use is the "timing hypothesis."
  • The "Timing Hypothesis" and HRT Risks:
    • Studies suggest that for healthy women, starting systemic HRT before age 60 or within 10 years of menopause may offer more benefits than risks.
    • The risk of certain side effects, particularly cardiovascular complications and blood clots, may be higher if systemic HRT is initiated more than 10 years after menopause or after age 60.

In conclusion, while the timing of systemic HRT initiation is a crucial factor in the overall risk-benefit analysis, data shows that treatment for vaginal and sexual symptoms with both local and systemic HRT remains effective regardless of whether it is started in perimenopause, menopause, or post-menopause.

Sources:

Initially created by Gemini (Google).

Retrieved from "https://riski.wiki/index.php?title=Vaginal_/_Sexual_and_HRT_Risks_in_Menopause/Data&oldid=90904"